Gut microbiota modulation in acute decompensation of liver cirrhosis: theory and therapeutic potential

Close metadata

OBJECTIVE

To show the rationale of gut microbiota modulation in acute decompensation of liver cirrhosis.

KEY POINTS

Despite the therapeutic strategies approved by current clinical recommendations, the development of acute decompensation of liver cirrhosis is characterized by an unfavorable prognosis and high mortality. Progress in understanding the underlying molecular mechanisms has led to the search for new interventions, drugs, and biological substances that can affect key links in the pathogenesis of the disease, for example, the impaired gut-liver axis and associated systemic inflammation. The potential for its regulation has emerged as one of the top concerns in modern hepatology, given that particular alterations in the composition and function of the gut microbiota play a crucial role here.

CONCLUSIONS

Despite the encouraging preliminary data, the majority of the suggested strategies for gut microbiota modulation have only been tested in animal models or in preliminary clinical trials; additional multicenter randomized controlled trials are required to demonstrate the efficacy of this strategy in larger patient populations.

Keywords:

gastrointestinal microbiome

gastroenterology

liver cirrhosis

inflammation

Authors:

Garbuzenko D.V.

South Ural State Medical University

Scopus AuthorID: 7801379382
ORCID: 0000-0001-9809-8015

Received:

05.08.2022

Accepted:

26.09.2022

List of references:

Jalan R, D’Amico G, Trebicka J, Moreau R, Angeli P, Arroyo V. New clinical and pathophysiological perspectives defining the trajectory of cirrhosis. Journal of Hepatology. 2021;75(suppl 1):14-26. https://doi.org/10.1016/j.jhep.2021.01.018
D’Amico G, Bernardi M, Angeli P. Towards a new definition of decompensated cirrhosis. Journal of Hepatology. 2022;76(1):202-207. https://doi.org/10.1016/j.jhep.2021.06.018
Moreau R, Jalan R, Gines P, Pavesi M, Angeli P, Cordoba J, Durand F, Gustot T, Saliba F, Domenicali M, Gerbes A, Wendon J, Alessandria C, Laleman W, Zeuzem S, Trebicka J, Bernardi M, Arroyo V; CANONIC Study Investigators of the EASL—CLIF Consortium. Acute-on-chronic liver failure is a distinct syndrome that develops in patients with acute decompensation of cirrhosis. Gastroenterology. 2013;144(7):1426-1437. https://doi.org/10.1053/j.gastro.2013.02.042
Trebicka J, Macnaughtan J, Schnabl B, Shawcross DL, Bajaj JS. The microbiota in cirrhosis and its role in hepatic decompensation. Journal of Hepatology. 2021;75(suppl 1):67-81. https://doi.org/10.1016/j.jhep.2020.11.013
Bajaj JS, O’Leary JG, Lai JC, Wong F, Long MD, Wong RJ, Kamath PS. Acute-on-Chronic Liver Failure Clinical Guidelines. American Journal of Gastroenterology. 2022;117(2):225-252. https://doi.org/10.14309/ajg.0000000000001595
Trebicka J, Fernandez J, Papp M, Caraceni P, Laleman W, Gambino C, Giovo I, Uschner FE, Jimenez C, Mookerjee R, Gustot T, Albillos A, Bañares R, Janicko M, Steib C, Reiberger T, Acevedo J, Gatti P, Bernal W, Zeuzem S, Zipprich A, Piano S, Berg T, Bruns T, Bendtsen F, Coenraad M, Merli M, Stauber R, Zoller H, Ramos JP, Solè C, Soriano G, de Gottardi A, Gronbaek H, Saliba F, Trautwein C, Özdogan OC, Francque S, Ryder S, Nahon P, Romero-Gomez M, Van Vlierberghe H, Francoz C, Manns M, Garcia E, Tufoni M, Amoros A, Pavesi M, Sanchez C, Curto A, Pitarch C, Putignano A, Moreno E, Shawcross D, Aguilar F, Clària J, Ponzo P, Jansen C, Vitalis Z, Zaccherini G, Balogh B, Vargas V, Montagnese S, Alessandria C, Bernardi M, Ginès P, Jalan R, Moreau R, Angeli P, Arroyo V; PREDICT STUDY group of the EASL-CLIF Consortium. The PREDICT study uncovers three clinical courses of acutely decompensated cirrhosis that have distinct pathophysiology. Journal of Hepatology. 2020;73(4):842-854. https://doi.org/10.1016/j.jhep.2020.06.013
Bernardi M, Caraceni P Novel perspectives in the management of decompensated cirrhosis. Nature Reviews Gastroenterology & Hepatology. 2018;15(12):753-764. https://doi.org/10.1038/s41575-018-0045-2
Queck A, Weiler N, Trebicka J. Transplantation in Acute-on-Chronic Liver Failure: Feasibility and Futility. Clinical Liver Disease (Hoboken). 2022;19(5):191-193. https://doi.org/10.1002/cld.1195
Caraceni P, Abraldes JG, Ginès P, Newsome PN, Sarin SK. The search for disease-modifying agents in decompensated cirrhosis: From drug repurposing to drug discovery. Journal of Hepatology. 2021;75(suppl 1):118-134. https://doi.org/10.1016/j.jhep.2021.01.024
Van der Merwe S, Chokshi S, Bernsmeier C, Albillos A. The multifactorial mechanisms of bacterial infection in decompensated cirrhosis. Journal of Hepatology. 2021;75(suppl 1):82-100. https://doi.org/10.1016/j.jhep.2020.11.029
Arroyo V, Angeli P, Moreau R, Jalan R, Clària J, Trebicka J, Fernández J, Gustot T, Caraceni P, Bernardi M; investigators from the EASL-CLIF Consortium, Grifols Chair and European Foundation for the Study of Chronic Liver Failure (EF-Clif). The systemic inflammation hypothesis: Towards a new paradigm of acute decompensation and multiorgan failure in cirrhosis. Journal of Hepatology. 2021;74(3):670-685. https://doi.org/10.1016/j.jhep.2020.11.048
Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Gut-liver axis in cirrhosis: Are hemodynamic changes a missing link? World Journal of Clinical Cases. 2021;9(31):9320-9332. https://doi.org/10.12998/wjcc.v9.i31.9320
Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Kudryavtseva A, Krasnov G. Gut dysbiosis and small intestinal bacterial overgrowth as independent forms of gut microbiota disorders in cirrhosis. World Journal of Gastroenterology. 2022;28(10):1067-1077. https://doi.org/10.3748/wjg.v28.i10.1067
Lunia MK, Sharma BC, Sachdeva S. Small intestinal bacterial overgrowth and delayed orocecal transit time in patients with cirrhosis and low-grade hepatic encephalopathy. Hepatology International. 2013;7(1):268-273. https://doi.org/10.1007/s12072-012-9360-9
Su T, Lai S, Lee A, He X, Chen S. Meta-analysis: proton pump inhibitors moderately increase the risk of small intestinal bacterial overgrowth. Journal of Gastroenterology. 2018;53(1):27-36. https://doi.org/10.1007/s00535-017-1371-9
Grace E, Shaw C, Whelan K, Andreyev HJ. Review article: small intestinal bacterial overgrowth--prevalence, clinical features, current and developing diagnostic tests, and treatment. Alimentary Pharmacology & Therapeutics. 2013;38(7):674-688. https://doi.org/10.1111/apt.12456
Acharya C, Bajaj JS. Gut Microbiota and Complications of Liver Disease. Gastroenterology Clinics of North America. 2017;46(1): 155-169. https://doi.org/10.1016/j.gtc.2016.09.013
Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, White MB, Monteith P, Noble NA, Unser AB, Daita K, Fisher AR, Sikaroodi M, Gillevet PM. Altered profile of human gut microbiome is associated with cirrhosis and its complications. Journal of Hepatology. 2014;60(5):940-947. https://doi.org/10.1016/j.jhep.2013.12.019
Di Lorenzo F, De Castro C, Silipo A, Molinaro A. Lipopolysaccharide structures of Gram-negative populations in the gut microbiota and effects on host interactions. FEMS Microbiology Reviews. 2019;43(3):257-272. https://doi.org/10.1093/femsre/fuz002
Shu W, Shanjian C, Jinpiao L, Qishui O. Gut microbiota dysbiosis in patients with hepatitis B virus-related cirrhosis. Annals of Hepatology. 2022;27(2):100676. https://doi.org/10.1016/j.aohep.2022.100676
Philips CA, Ahamed R, Abduljaleel JKP, Rajesh S, Augustine P. Identification and Analysis of Gut Microbiota and Functional Metabolism in Decompensated Cirrhosis with Infection. Journal of Clinical and Translational Hepatology. Published online: Jun 13, 2022. https://doi.org/10.14218/JCTH.2021.00428
Bajaj JS, Vargas HE, Reddy KR, Lai JC, O’Leary JG, Tandon P, Wong F, Mitrani R, White MB, Kelly M, Fagan A, Patil R, Sait S, Sikaroodi M, Thacker LR, Gillevet PM. Association Between Intestinal Microbiota Collected at Hospital Admission and Outcomes of Patients With Cirrhosis. Clinical Gastroenterology and Hepatology. 2019;17(4):756-765. https://doi.org/10.1016/j.cgh.2018.07.022
Maslennikov R, Ivashkin V, Efremova I, Alieva A, Kashuh E, Tsvetaeva E, Poluektova E, Shirokova E, Ivashkin K. Gut dysbiosis is associated with poorer long-term prognosis in cirrhosis. World Journal of Hepatology. 2021;13(5):557-570. https://doi.org/10.4254/wjh.v13.i5.557
Sorribas M, Jakob MO, Yilmaz B, Li H, Stutz D, Noser Y, de Gottardi A, Moghadamrad S, Hassan M, Albillos A, Francés R, Juanola O, Spadoni I, Rescigno M, Wiest R. FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis. Journal of Hepatology. 2019;71(6):1126-1140. https://doi.org/10.1016/j.jhep.2019.06.017
Farooqui N, Elhence A, Shalimar. A Current Understanding of Bile Acids in Chronic Liver Disease. Journal of Clinical and Experimental Hepatology. 2022;12(1):155-173. https://doi.org/10.1016/j.jceh.2021.08.017
Shao JW, Ge TT, Chen SZ, Wang G, Yang Q, Huang CH, Xu LC, Chen Z. Role of bile acids in liver diseases mediated by the gut microbiome. World Journal of Gastroenterology. 2021;27(22): 3010-3021. https://doi.org/10.3748/wjg.v27.i22.3010
Lorenzo-Zúñiga V, Bartolí R, Planas R, Hofmann AF, Viñado B, Hagey LR, Hernández JM, Mañé J, Alvarez MA, Ausina V, Gassull MA. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology. 2003;37(3):551-557. https://doi.org/10.1053/jhep.2003.50116
Chen P, Stärkel P, Turner JR, Ho SB, Schnabl B. Dysbiosis-induced intestinal inflammation activates tumor necrosis factor receptor I and mediates alcoholic liver disease in mice. Hepatology. 2015;61(3):883-894. https://doi.org/10.1002/hep.27489
Garbuzenko DV. The role of intestinal microflora in the development of complications of hepatic cirrhosis-associated portal hypertension. Klinicheskaia meditsina (Moskva). 2007;85(8):15-19. (In Rus.).
Alexopoulou A, Agiasotelli D, Vasilieva LE, Dourakis SP. Bacterial translocation markers in liver cirrhosis. Annals of Gastroenterology. 2017;30(5):486-497. https://doi.org/10.20524/aog.2017.0178
Philips CA, Augustine P. Gut Barrier and Microbiota in Cirrhosis. Journal of Clinical and Experimental Hepatology. 2022;12(2): 625-638. https://doi.org/10.1016/j.jceh.2021.08.027
Ponziani FR, Zocco MA, Cerrito L, Gasbarrini A, Pompili M. Bacterial translocation in patients with liver cirrhosis: physiology, clinical consequences, and practical implications. Expert Review of Gastroenterology & Hepatology. 2018;12(7):641-656. https://doi.org/10.1080/17474124.2018.1481747
Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. Journal of Physiology. 2012;590(3):447-458. https://doi.org/10.1113/jphysiol.2011.219691
Piñero P, Juanola O, Caparrós E, Zapater P, Giménez P, González-Navajas JM, Such J, Francés R. Toll-like receptor polymorphisms compromise the inflammatory response against bacterial antigen translocation in cirrhosis. Scientific Reports. 2017;7: 46425. https://doi.org/10.1038/srep46425
Swanson KV, Deng M, Ting JP. The NLRP3 inflammasome: molecular activation and regulation to therapeutics. Nature Reviews Immunology. 2019;19(8):477-489. https://doi.org/10.1038/s41577-019-0165-0
Albillos A, Lario M, Álvarez-Mon M. Cirrhosis-associated immune dysfunction: distinctive features and clinical relevance. Journal of Hepatology. 2014;61(6):1385-1396. https://doi.org/10.1016/j.jhep.2014.08.010
European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. Journal of Hepatology. 2018;69(2):406-460. https://doi.org/10.1016/j.jhep.2018.03.024
Albillos A, de Gottardi A, Rescigno M. The gut-liver axis in liver disease: Pathophysiological basis for therapy. Journal of Hepatology. 2020;72(3):558-577. https://doi.org/10.1016/j.jhep.2019.10.003
Ivashkin VT, Maevskaya MV, Zharkova MS, Zhigalova SB, Kitsenko EA, Manukyan GV, Trukhmanov AS, Maev IV, Tikhonov IN, Deeva TA. Clinical Recommendations of the Russian Scientific Liver Society and Russian Gastroenterological Association on Diagnosis and Treatment of Liver Fibrosis, Cirrhosis and Their Complications. Rossijskij zhurnal gastrojenterologii, gepatologii, koloproktologii. 2021;31(6):56-102. (In Rus.).
Albillos A, de la Hera A, González M, Moya JL, Calleja JL, Monserrat J, Ruiz-del-Arbol L, Alvarez-Mon M. Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement. Hepatology. 2003;37(1):208-217. https://doi.org/10.1053/jhep.2003.50038
Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d’Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, Valla D, Gault N, Lebrec D; NORFLOCIR Trial Investigators. Effects of Long-term Norfloxacin Therapy in Patients With Advanced Cirrhosis. Gastroenterology. 2018;155(6):1816-1827. https://doi.org/10.1053/j.gastro.2018.08.026
de Lastours V, Fantin B. Impact of fluoroquinolones on human microbiota. Focus on the emergence of antibiotic resistance. Future Microbiology. 2015;10(7):1241-1255. https://doi.org/10.2217/fmb.15.40
Kimer N, Pedersen JS, Tavenier J, Christensen JE, Busk TM, Hobolth L, Krag A, Al-Soud WA, Mortensen MS, Sørensen SJ, Møller S, Bendtsen F; members of the CoRif study group. Rifaximin has minor effects on bacterial composition, inflammation, and bacterial translocation in cirrhosis: A randomized trial. Journal of Gastroenterology and Hepatology. 2018;33(1):307-314. https://doi.org/10.1111/jgh.13852
Kaji K, Saikawa S, Takaya H, Fujinaga Y, Furukawa M, Kitagawa K, Ozutsumi T, Kaya D, Tsuji Y, Sawada Y, Kawaratani H, Moriya K, Namisaki T, Akahane T, Mitoro A, Yoshiji H. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients. Antibiotics (Basel). 2020;29;9(4):145. https://doi.org/10.3390/antibiotics9040145
Soni H, Kumar-M P, Sharma V, Bellam BL, Mishra S, Mahendru D, Mandavdhare HS, Medhi B, Dutta U, Singh V. Antibiotics for prophylaxis of spontaneous bacterial peritonitis: systematic review & Bayesian network meta-analysis. Hepatology International. 2020;14(3):399-413. https://doi.org/10.1007/s12072-020-10025-1
Maslennikov R, Ivashkin V, Efremova I, Poluektova E, Shirokova E. Probiotics in hepatology: An update. World Journal of Hepatology. 2021;13(9):1154-1166. https://doi.org/10.4254/wjh.v13.i9.1154
Rashid SK, Idris-Khodja N, Auger C, Alhosin M, Boehm N, Oswald-Mammosser M, Schini-Kerth VB. Probiotics (VSL#3) prevent endothelial dysfunction in rats with portal hypertension: role of the angiotensin system. PLoS One. 2014;9(5):e97458. https://doi.org/10.1371/journal.pone.0097458
Sánchez E, Nieto JC, Boullosa A, Vidal S, Sancho FJ, Rossi G, Sancho-Bru P, Oms R, Mirelis B, Juárez C, Guarner C, Soriano G. VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. Liver International. 2015;35(3):735-745. https://doi.org/10.1111/liv.12566
Moratalla A, Gómez-Hurtado I, Santacruz A, Moya Á, Peiró G, Zapater P, González-Navajas JM, Giménez P, Such J, Sanz Y, Francés R. Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis. Liver International. 2014;34(6):850-858. https://doi.org/10.1111/liv.12380
Moratalla A, Caparrós E, Juanola O, Portune K, Puig-Kröger A, Estrada-Capetillo L, Bellot P, Gómez-Hurtado I, Piñero P, Zapater P, González-Navajas JM, Such J, Sanz Y, Francés R. Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis. Journal of Hepatology. 2016;64(1):135-145. https://doi.org/10.1016/j.jhep.2015.08.020
Xia X, Chen J, Xia J, Wang B, Liu H, Yang L, Wang Y, Ling Z. Role of probiotics in the treatment of minimal hepatic encephalopathy in patients with HBV-induced liver cirrhosis. Journal of International Medical Research. 2018;46(9):3596-3604. https://doi.org/10.1177/0300060518776064
Koga H, Tamiya Y, Mitsuyama K, Ishibashi M, Matsumoto S, Imaoka A, Hara T, Nakano M, Ooeda K, Umezaki Y, Sata M. Probiotics promote rapid-turnover protein production by restoring gut flora in patients with alcoholic liver cirrhosis. Hepatology International. 2013;7(2):767-774. https://doi.org/10.1007/s12072-012-9408-x
Macnaughtan J, Figorilli F, García-López E, Lu H, Jones H, Sawhney R, Suzuki K, Fairclough S, Marsden J, Moratella A, Cox IJ, Thomas L, Davies N, Williams R, Mookerjee R, Wright G, Jalan R. A Double-Blind, Randomized Placebo-Controlled Trial of Probiotic Lactobacillus casei Shirota in Stable Cirrhotic Patients. Nutrients. 2020;12(6):1651. https://doi.org/10.3390/nu12061651
Bajaj JS, Heuman DM, Hylemon PB, Sanyal AJ, Puri P, Sterling RK, Luketic V, Stravitz RT, Siddiqui MS, Fuchs M, Thacker LR, Wade JB, Daita K, Sistrun S, White MB, Noble NA, Thorpe C, Kakiyama G, Pandak WM, Sikaroodi M, Gillevet PM. Randomised clinical trial: Lactobacillus GG modulates gut microbiome, metabolome and endotoxemia in patients with cirrhosis. Alimentary Pharmacology & Therapeutics. 2014;39(10):1113-1125. https://doi.org/10.1111/apt.12695
Horvath A, Leber B, Schmerboeck B, Tawdrous M, Zettel G, Hartl A, Madl T, Stryeck S, Fuchs D, Lemesch S, Douschan P, Krones E, Spindelboeck W, Durchschein F, Rainer F, Zollner G, Stauber RE, Fickert P, Stiegler P, Stadlbauer V. Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis. Alimentary Pharmacology & Therapeutics. 2016;44(9):926-935. https://doi.org/10.1111/apt.13788
Horvath A, Durdevic M, Leber B, di Vora K, Rainer F, Krones E, Douschan P, Spindelboeck W, Durchschein F, Zollner G, Stauber RE, Fickert P, Stiegler P, Stadlbauer V. Changes in the Intestinal Microbiome during a Multispecies Probiotic Intervention in Compensated Cirrhosis. Nutrients. 2020;12(6):1874. https://doi.org/10.3390/nu12061874
Bajaj JS, Khoruts A. Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis. Journal of Hepatology. 2020;72(5):1003-1027. https://doi.org/10.1016/j.jhep.2020.01.017
Segal JP, Mullish BH, Quraishi MN, Iqbal T, Marchesi JR, Sokol H. Mechanisms underpinning the efficacy of faecal microbiota transplantation in treating gastrointestinal disease. Therapeutic Advances in Gastroenterology. 2020;13:1756284820946904. https://doi.org/10.1177/1756284820946904
Hassouneh R, Bajaj JS. Gut Microbiota Modulation and Fecal Transplantation: An Overview on Innovative Strategies for Hepatic Encephalopathy Treatment. Journal of Clinical Medicine. 2021;10(2):330. https://doi.org/10.3390/jcm10020330
Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017;66(6):1727-1738. https://doi.org/10.1002/hep.29306
Bajaj JS, Fagan A, Gavis EA, Kassam Z, Sikaroodi M, Gillevet PM. Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis. Gastroenterology. 2019;156(6):1921-1923. https://doi.org/10.1053/j.gastro.2019.01.033
Bajaj JS, Salzman NH, Acharya C, Sterling RK, White MB, Gavis EA, Fagan A, Hayward M, Holtz ML, Matherly S, Lee H, Osman M, Siddiqui MS, Fuchs M, Puri P, Sikaroodi M, Gillevet PM. Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial. Hepatology. 2019;70(5):1690-1703. https://doi.org/10.1002/hep.30690
Gupta S, Mullish BH, Allegretti JR. Fecal Microbiota Transplantation: The Evolving Risk Landscape. American Journal of Gastroenterology. 2021;116(4):647-56. https://doi.org/10.14309/ajg.0000000000001075
US Food and Drug Administration. Information pertaining to additional safety protections regarding use of fecal microbiota for transplantation — screening and testing of stool donors for multi-drug resistant organisms.2019. Accessed June 30, 2020. https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/information-pertaining-additional-safety-protections-regarding-use-fecal-microbiota-transplantation
Han C, Duan C, Zhang S, Spiegel B, Shi H, Wang W, Zhang L, Lin R, Liu J, Ding Z, Hou X. Digestive Symptoms in COVID-19 Patients With Mild Disease Severity: Clinical Presentation, Stool Viral RNA Testing, and Outcomes. American Journal of Gastroenterology. 2020;115(6):916-923. https://doi.org/10.14309/ajg.0000000000000664
Ianiro G, Mullish BH, Kelly CR, Kassam Z, Kuijper EJ, Ng SC, Iqbal TH, Allegretti JR, Bibbò S, Sokol H, Zhang F, Fischer M, Costello SP, Keller JJ, Masucci L, van Prehn J, Quaranta G, Quraishi MN, Segal J, Kao D, Satokari R, Sanguinetti M, Tilg H, Gasbarrini A, Cammarota G. Reorganisation of faecal microbiota transplant services during the COVID-19 pandemic. Gut. 2020;69(9):1555-1563. https://doi.org/10.1136/gutjnl-2020-321829
Yan K, Hung A, Parmer C, Yang H, Jain D, Lim B, Goodman AL, Garcia-Tsao G. Obeticholic Acid Decreases Intestinal Content of Enterococcus in Rats With Cirrhosis and Ascites. Hepatology Communications. 2021;5(9):1507-1517. https://doi.org/10.1002/hep4.1740
Úbeda M, Lario M, Muñoz L, Borrero MJ, Rodríguez-Serrano M, Sánchez-Díaz AM, Del Campo R, Lledó L, Pastor Ó, García-Bermejo L, Díaz D, Álvarez-Mon M, Albillos A. Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats. Journal of Hepatology. 2016;64(5):1049-1057. https://doi.org/10.1016/j.jhep.2015.12.010
Verbeke L, Mannaerts I, Schierwagen R, Govaere O, Klein S, Vander Elst I, Windmolders P, Farre R, Wenes M, Mazzone M, Nevens F, van Grunsven LA, Trebicka J, Laleman W. FXR agonist obeticholic acid reduces hepatic inflammation and fibrosis in a rat model of toxic cirrhosis. Scientific Reports. 2016;6:33453. https://doi.org/10.1038/srep33453
Tripisciano C, Kozynchenko OP, Linsberger I, Phillips GJ, Howell CA, Sandeman SR, Tennison SR, Mikhalovsky SV, Weber V, Falkenhagen D. Activation-dependent adsorption of cytokines and toxins related to liver failure to carbon beads. Biomacromolecules. 2011;12(10):3733-3740. https://doi.org/10.1021/bm200982g
Macnaughtan J, Ranchal I, Soeda J, Sawhney R, Oben J, Davies N, Mookerjee R, Marchesi J, Cox J, Jalan R. Oral therapy with non-absorbable carbons of controlled porosity (YAQ-001) selectively modulates stool microbiome and its function and this is associated with restoration of immune function and inflammasome activation. Journal of Hepatology. 2015;62(suppl 2):S240. https://doi.org/10.1016/S0168-8278(15)30110-0
Macnaughtan1 J, Albillos A, Kerbert A, Vargas V, Durand F, Gines P. A double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent Carbalive (Yaq-001) in cirrhotic patients. Gut. 2021;70(suppl 3):A5-A6. https://doi.org/10.1136/gutjnl-2021-BASL.9

Close metadata